Compare Primo Brands Corporation Class A Common Stock (PRMB) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Primo Brands Corporation Class A Common Stock vs Vertex Pharmaceuticals Incorporated — how do they compare? Primo Brands Corporation Class A Common Stock trades at $18.76 (market cap $6.84B), while Vertex Pharmaceuticals Incorporated trades at $504.96 (market cap $122.98B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 18× Primo Brands Corporation Class A Common Stock's market cap, and Primo Brands Corporation Class A Common Stock pays a 2.54% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Primo Brands Corporation Class A Common Stock for 0 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| PRMB | VRTX | |
|---|---|---|
Market Cap | $6.84B | $122.98B |
Volume | 2,864,594 | 1,155,743 |
Sector | Consumer Staples | Health |
52-Week High | $25.39 | $557.96 |
52-Week Low | $14.46 | $407.90 |
Typical Hold Time | 0 Days | 120 Days |
Enterprise Value | $12.17B | $117.11B |
Dividend Yield | 2.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PRMB trades at $18.9, down 1.46% on the day, with a neutral technical signal and key support/resistance clustered around $19. The company reported Q2 2026 EPS of $0.37, beating expectations, and shows improving revenue and net income trends for 2026. Recent news highlights expansion with a new factory opening and strong premium water sales growth, supporting a positive analyst consensus.
The outlook is positive, driven by sales momentum and capacity expansion, but risks include thin net margins and high P/E ratio. With 80% of analysts rating it Buy and a consensus price target of $28.50, the stock offers significant upside potential if execution continues, though margin pressure remains a key watchpoint.
Vertex Pharmaceuticals (VRTX) trades at $498.50, down 1.68% amid mixed technical signals. The stock shows strong fundamentals with $12B revenue, 35% net margins, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Technical indicators show bearish momentum with support at $496 and resistance at $512.
Outlook remains positive with 86% analyst buy ratings and $573.50 price target. Key risks include clinical trial outcomes and competitive pressures. The company's expanding pipeline and profitability provide upside potential, though near-term volatility may persist around key technical levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Primo Brands Corporation Class A Common Stock
Primo Brands Corporation is a branded beverage company that produces and distributes packaged and purified water, water dispensers, and filtration equipment across North America, under brands including Poland Spring, Pure Life, Arrowhead, and Primo Water.
Read more on PRMB →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
